CN111419780A - Facial composition and application thereof - Google Patents
Facial composition and application thereof Download PDFInfo
- Publication number
- CN111419780A CN111419780A CN202010376481.1A CN202010376481A CN111419780A CN 111419780 A CN111419780 A CN 111419780A CN 202010376481 A CN202010376481 A CN 202010376481A CN 111419780 A CN111419780 A CN 111419780A
- Authority
- CN
- China
- Prior art keywords
- facial
- composition
- face
- facial composition
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/85—Polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a composition for face, which belongs to the technical field of beauty treatment and comprises the components of hyaluronic acid, botulinum toxin, poly-L-lactic acid, placental peptide, collagen, lidocaine, liposoluble needle and normal saline. The facial composition provided by the invention can tighten the facial skin, promote the facial contour, repair the facial depression and cause little pain.
Description
Technical Field
The invention belongs to the technical field of beauty treatment, and particularly relates to a facial composition and application thereof.
Background
With the continuous improvement of the living standard of people, people pay more and more attention to the beauty of the people and pay more and more attention to facial skin problems, the facial skin problems mainly comprise looseness, sag, droop, atrophy, shriveling, spots, fine lines, dryness, large pores, sensitivity, roughness and the like, and the existing solutions for the facial skin aging and the skin problems are not satisfactory.
In the prior art, facial skin is tightened by adopting various methods, for example, the facial contour is lifted by adopting the traditional skin-pulling operation, so that the effect of tightening the facial skin is achieved, the skin-pulling operation is to design an incision line beside or behind the ear in the forehead and temporal hair, cut the skin, peel off along a subcutaneous fat layer by using an operation instrument, effectively stimulate collagen recombination, then tighten the loose skin of the face towards the back upper part or tighten a deep fascia layer of the face, cut off redundant skin, suture the incision, and finally achieve the effects of tightening the skin and reducing wrinkles.
Disclosure of Invention
In view of the above, the present invention aims to provide a facial composition and an application thereof, and the facial composition provided by the present invention can tighten facial skin, increase facial contour, repair facial depression and cause little pain.
In order to achieve the above purpose, the invention provides the following technical scheme:
the invention provides a facial composition, which comprises the components of hyaluronic acid, botulinum toxin, poly-L-lactic acid, placental peptide, collagen, lidocaine, liposoluble needle and normal saline.
Preferably, the mass ratio of the hyaluronic acid, the botulinum toxin, the poly-L-lactic acid, the placental peptide, the collagen, the lidocaine, the liposoluble needle and the normal saline is 15-30: 5-10: 3-8: 15-25: 3-15: 10-20: 5-25.
Preferably, the mass ratio of the hyaluronic acid to the botulinum toxin to the poly-L-lactic acid to the placental peptide to the collagen to the lidocaine to the liposoluble needle to the physiological saline is 29:9:7:5:23:5:12: 10.
The invention also provides application of the facial composition in the technical scheme in facial skin tightening.
The invention also provides application of the facial composition in the technical scheme in face contour improvement.
The invention also provides application of the facial composition in the technical scheme in facial depression repair.
Preferably, the dosage of the face composition is 1-100 ml each time.
Preferably, the total number of uses of the facial composition is 1 to 6.
The invention provides a facial composition, which comprises the components of hyaluronic acid, botulinum toxin, poly-L-lactic acid, placental peptide, collagen, lidocaine, liposoluble needle and normal saline.
Drawings
FIG. 1 is a graph comparing the effects of the subject of example 2 after use of the facial composition;
FIG. 2 is a graph comparing the effects of the subject of example 3 after use of the facial composition;
FIG. 3 is a graph comparing the effects of the subject of example 4 after use of the facial composition;
FIG. 4 is a graph comparing the effects of the subject of example 5 after use of the facial composition;
FIG. 5 is a graph comparing the effects of the subject of example 6 after use of the facial composition;
FIG. 6 is a graph comparing the effects of the subject of example 7 after use of the facial composition;
FIG. 7 is a graph comparing the effects of the subject of example 8 after use of the facial composition;
FIG. 8 is a graph comparing the effects of the subject of example 9 after use of the facial composition;
FIG. 9 is a graph comparing the effects of the subject of example 10 after use of the facial composition;
FIG. 10 is a graph comparing the effects of the subject of example 11 after using the facial composition;
FIG. 11 is a graph comparing the effects of the subject of example 12 after use of the facial composition;
FIG. 12 is a graph comparing the effects of the subject of example 13 after use of the facial composition;
FIG. 13 is a graph comparing the effects of the subject of example 14 after use of the facial composition;
FIG. 14 is a graph comparing the effects of the subject of example 15 after use of the facial composition;
FIG. 15 is a graph showing a comparison of the effects of the subjects of comparative example 1 after hyaluronic acid administration.
Detailed Description
The invention provides a facial composition, which comprises the components of hyaluronic acid, botulinum toxin, poly-L-lactic acid, placental peptide, collagen, lidocaine, liposoluble needle and normal saline. In the invention, the mass ratio of the hyaluronic acid, the botulinum toxin, the poly-L-lactic acid, the placental peptide, the collagen, the lidocaine, the liposoluble needle and the normal saline is preferably 15-30: 5-10: 3-8: 15-25: 3-15: 10-20: 5-25, and more preferably 29:9:7:5:23:5:12: 10.
In the present invention, the hyaluronic acid functions as: 1. increase the elasticity of the skin; 2. water retention and locking; 3. removing wrinkles, plumping lips, humping nose, plumping forehead, filling dents, etc. The source of the hyaluronic acid is not particularly limited, and the hyaluronic acid can be obtained by adopting conventional commercially available products. In the invention, the hyaluronic acid is divided into three kinds of hyaluronic acid molecules, namely large, medium and small hyaluronic acid molecules, the particle size of the large hyaluronic acid molecule is large, and the absorption and metabolism time of a human body is slow and the duration time is long.
In the present invention, the effect of the botulinum toxin is: the muscle fibers can not be contracted to cause the muscle to be relaxed, thereby achieving the purpose of removing wrinkles and beautifying. The source of the botulinum toxin is not particularly limited in the present invention, and any conventional commercially available product may be used, and in the present invention, the botulinum toxin is preferably obtained from botulinum toxin type A for injection sold by Duty corporation of Lanzhou Biopreparation research institute.
In the invention, the poly-L-lactic acid stimulates the secondary activity of cells and stimulates the increase of collagen of the body to achieve the effects of resisting aging and preventing aging after being injected. In the invention, the poly-L-lactic acid belongs to recurrent medicine, can increase the collagen content of the body, and has slow collagen loss. In the present invention, the poly (L-lactic acid) is preferably a poly (L-lactic acid) obtained from Pilea baiensis, Teddy, Zhejiang.
In the present invention, the placental peptide functions as: 1. inhibiting inflammation and resisting allergy; 2. beautifying and protecting the skin: whitening, improving rough skin, loose muscle, increasing wrinkles, removing freckles, whitening, preventing skin tension reduction, moistening and smoothing skin, improving and maintaining elasticity of muscle and the like; 3. regulating and balancing endocrine, prolonging puberty, and resisting aging, and can be used for recovering physical strength and energy of the elderly and promoting cell regeneration. The source of the placental peptide is not particularly limited, and the placental peptide can be obtained by using a conventional commercial product.
The collagen in the facial composition provided by the invention has the following functions: improving the wrinkles, lip lines, eyebrow lines and other conditions of the face, effectively supplementing the defects of the dermis and achieving the purpose of repairing the wrinkles. In the present invention, the collagen is preferably a collagen commercially available from Shuangmei Biotech, Inc. of Taiwan.
The present invention provides a composition for the face, wherein the composition for the face contains licarbazepine and a local anesthetic. The source of the licarbadoxine is not particularly limited in the invention, and the licarbadoxine can be prepared from conventional commercial products, and in the specific embodiment of the invention, the licarbadoxine is preferably purchased from lidocaine hydrochloride injection sold in Jiupai of Hebei.
The fat dissolving needle in the facial composition provided by the invention has the functions of eliminating stubborn proud flesh and improving skin texture. The source of the liposoluble needle is not particularly limited, and the liposoluble needle can be obtained by adopting conventional commercial products, and is preferably purchased from Gubin liposoluble needles sold by Naesen medical beauty treatment Co., Ltd, Guangzhou.
The preparation method of the facial composition is not particularly limited, and the components are uniformly mixed by adopting a conventional method, and the preparation method specifically comprises the step of uniformly mixing through a three-way pipe.
The invention also provides application of the facial composition in the technical scheme in facial skin tightening.
The invention also provides application of the facial composition in the technical scheme in face contour improvement.
The invention also provides application of the facial composition in the technical scheme in facial depression repair.
In the present invention, when used for the forehead, the amount of the composition for the face is preferably 8 to 12 ml; when the face composition is used for temples, the dosage of the face composition is preferably 8-12 ml; when the facial composition is used for lacrimal canaliculus, the dosage of the facial composition is preferably 1-3 ml; when the face composition is used for the nose, the dosage of the face composition is preferably 1-3 ml; when the face composition is used for a middle face, the dosage of the face composition is preferably 5-10 ml; when the face composition is applied to the cheek, the dosage of the face composition is preferably 3-8 ml; when the face composition is used for the lower jaw, the dosage of the face composition is preferably 1-5 ml. In the present invention, the total number of times of use of the composition for face is preferably 1 to 6 times.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
The composition for the face comprises hyaluronic acid, botulinum toxin, poly-L-lactic acid, placental peptide, collagen, lidocaine, a lipolysis needle and normal saline, wherein the mass ratio of hyaluronic acid, botulinum toxin, poly-L-lactic acid, placental peptide, collagen, lidocaine, the lipolysis needle and the normal saline is 29:9:7:5:23:5:12: 10. Repeatedly sucking and mixing the above components uniformly by using a tee pipe to obtain the facial composition.
Application effects of the facial composition of example 1:
example 2
Site of subject to which the facial composition of example 1 was injected: temple < temple >, left: 3ml right: 3 ml; apple muscle: 6 ml; lacrimal canals: 1 ml; when in use: for 10 minutes.
Effect (fig. 1): the depressions are filled, the lines are soft, and the face is young.
Example 3
Injection site of subject into the facial composition of example 1 cheek site: left: 3ml right: 3 ml; temple < temple >: 8ml of the solution; when in use: for 20 minutes.
Effect (fig. 2): the depressions are filled, the lines are soft, and the face is young.
Example 4
Injection site of subject into which the facial composition of example 1 was injected: cheek fat: 10 ml; chin (lower jaw): 5ml of the solution; when in use: for 15 minutes.
Effect (fig. 3): repairing the middle and lower face defects, tightening cheek fat and dissolving fat; the width of the lower atrium before fat dissolution is 17cm, and the thickness of the cheek fat pad is 3.5 cm; after fat dissolving, the width of the lower court is 14cm, and the thickness of the cheek fat pad is 2.5 cm.
Example 5
Injection site of subject into which the facial composition of example 1 was injected: cheek fat: 5ml, left 2ml and right 3 ml; the lower jaw masseter part: 3ml, left 1.5ml and right 1.5 ml; when in use: for 20 minutes.
Effect (fig. 4): the fat pad of cheek tightens up, dissolves fat, and the masseter tightens up, reaches the line and compacts, and the profile is clear.
Example 6
Injection site of subject into which the facial composition of example 1 was injected: temple < temple >: 6 ml; cheek area: 6 ml; 2ml of nasal fundus < alar nasal wall; the statute line: 2 ml; when in use: for 30 minutes.
Effect (fig. 5): the lines of the face are softened, the face is young, and the pits are filled.
Example 7
Injection site of subject into which the facial composition of example 1 was injected: forehead position: 5ml of the solution; 6ml of apple flesh; temple < temple >: 6 ml; cheek area: 6 ml; the statute line: 2 ml; when in use: for 40 minutes.
Effect (fig. 6): the lines of the face are softened, the face is young, and the pits are filled.
Example 8
Injection site of subject into which the facial composition of example 1 was injected: lacrimal canals: 3 ml; 6ml of apple flesh; cheek fat: 6 ml; the statute line: 2 ml; mandibular masseter muscle: 2 ml; when in use: for 50 minutes.
Effect (fig. 7): the facial fat is tightened and dissolved, and the face is younger.
Example 9
Injection site of subject into which the facial composition of example 1 was injected: forehead position: 3 ml; 6ml of apple flesh; temple < temple >: 6 ml; cheek fat: 6 ml; the statute line: 3 ml; cheek recession: 4 ml; when in use: for 40 minutes.
Effect (fig. 8): tightening and fat dissolving of facial fat, softening facial lines, youthful face and filling depressions.
Example 10
Injection site of subject into which the facial composition of example 1 was injected: 2ml of eyebrow; eyebrow center: 1 ml; temple < temple >: 8ml of the solution; when in use: for 20 minutes.
Effect (fig. 9): the facial lines are softened and filled in the pits.
Example 11
Injection site of subject into which the facial composition of example 1 was injected: temple < temple >: 6 ml; lacrimal canals: 1 ml; the statute line: 3 ml; when in use: for 15 minutes.
Effect (fig. 10): the lines of the face are softened, the face is young, and the pits are filled.
Example 12
Injection site of subject into which the facial composition of example 1 was injected: the mandible tip: 3 ml; lower jaw edge: 6 ml; when in use: 15 minutes
Effect (fig. 11): the facial lines are softened, and the middle lower surface is filled with pits.
Example 13
Injection site of subject into which the facial composition of example 1 was injected: lacrimal canals: 2 ml; forehead position: 3 ml; apple flesh 2 ml; cheek fat: 6 ml; the statute line: 3 ml; cheek recession: 2 ml; the mandible tip: 2 ml; root of the nose: 1 ml; when in use: for 60 minutes.
Effect (fig. 12): tightening and fat dissolving of facial fat, softening facial lines, youthful face and filling depressions.
Example 14
Injection site of subject into which the facial composition of example 1 was injected: forehead position: 3 ml; temple < temple >: 2 ml; cheek fat: 8ml of the solution; the statute line: 3 ml; mandibular masseter muscle: 2 ml; the mandible tip: 1 ml; when in use: for 50 minutes.
Effect (fig. 13): tightening and fat dissolving of facial fat, softening facial lines, youthful face and filling depressions.
Example 15
Injection site of subject into which the facial composition of example 1 was injected: forehead position: 3 ml; 5ml of apple flesh; temple < temple >: 6 ml; cheek fat: 6 ml; the statute line: 3 ml; mandibular masseter muscle: 3 ml; lacrimal canals: 2 ml; when in use: for 40 minutes.
Effect (fig. 14): tightening and fat dissolving of facial fat, softening facial lines, youthful face and filling depressions.
Comparative example 1
Subjects injected with hyaluronic acid, site: temple < temple >, left: 3ml, right: 3 ml; apple muscle: 6 ml; lacrimal canals: 1 ml; when in use: for 10 minutes.
Effect (fig. 15): the pain is strong, the maintenance time is short, and the effect is not obvious.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (8)
1. A facial composition, wherein the components of said facial composition comprise hyaluronic acid, botulinum toxin, poly-L-lactic acid, placental peptide, collagen, lidocaine, liposoluble needles and physiological saline.
2. The facial composition according to claim 1, wherein the mass ratio of hyaluronic acid, botulinum toxin, poly-L-lactic acid, placental peptide, collagen, lidocaine, liposoluble needles and physiological saline is 15-30: 5-10: 3-8: 15-25: 3-15: 10-20: 5-25.
3. The facial composition according to claim 2, wherein the mass ratio of hyaluronic acid, botulinum toxin, poly-L-lactic acid, placental peptide, collagen, lidocaine, liposoluble needles and physiological saline is 29:9:7:5:23:5:12: 10.
4. Use of a facial composition as claimed in any one of claims 1 to 3 for facial skin tightening.
5. Use of the facial composition of any one of claims 1 to 3 to enhance the facial profile.
6. Use of the facial composition of any one of claims 1 to 3 for facial depression repair.
7. The use according to any one of claims 4 to 6, wherein the facial composition is used in an amount of 1 to 100ml per application.
8. The use according to any one of claims 4 to 6, wherein the facial composition is used from 1 to 6 times in total.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010376481.1A CN111419780A (en) | 2020-05-07 | 2020-05-07 | Facial composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010376481.1A CN111419780A (en) | 2020-05-07 | 2020-05-07 | Facial composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111419780A true CN111419780A (en) | 2020-07-17 |
Family
ID=71555001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010376481.1A Pending CN111419780A (en) | 2020-05-07 | 2020-05-07 | Facial composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111419780A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113081896A (en) * | 2021-05-10 | 2021-07-09 | 拉菲尔(深圳)投资咨询有限公司 | Regenerative medical injection for facial rejuvenation and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524657A (en) * | 2014-12-15 | 2015-04-22 | 方跃明 | Method related to biological agent three-dimensional cosmetic injection |
| CN105534783A (en) * | 2015-12-29 | 2016-05-04 | 杭州芭黎雅医疗美容诊所有限公司 | Autologous collagen baby-face-preserving composition and method for preparing composition |
| CN106176292A (en) * | 2016-07-16 | 2016-12-07 | 江苏华亿美素生物组织工程有限公司 | A kind of biodegradable injection molding process decorative material and preparation method thereof |
| CN107185042A (en) * | 2017-04-29 | 2017-09-22 | 杭州维多利亚医疗美容医院有限公司 | A kind of beauty injection and preparation method thereof |
| CN108324673A (en) * | 2018-02-06 | 2018-07-27 | 宁波东钱湖旅游度假区靖芮医疗美容诊所有限公司 | A kind of face mesenchyma is against age method for customizing |
| CN109528642A (en) * | 2018-12-27 | 2019-03-29 | 上海欧邦医疗管理有限公司 | A kind of autogenous repairing nutrient injection and its application method |
| CN110075366A (en) * | 2019-04-01 | 2019-08-02 | 杨青青 | A kind of anti-oxidant lifting esthetic line of biological absorbable and its preparation method and application |
| CN110368486A (en) * | 2019-08-16 | 2019-10-25 | 重庆新铜雀台整形美容医院有限公司 | A kind of injection for facial fat metabolism |
-
2020
- 2020-05-07 CN CN202010376481.1A patent/CN111419780A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524657A (en) * | 2014-12-15 | 2015-04-22 | 方跃明 | Method related to biological agent three-dimensional cosmetic injection |
| CN105534783A (en) * | 2015-12-29 | 2016-05-04 | 杭州芭黎雅医疗美容诊所有限公司 | Autologous collagen baby-face-preserving composition and method for preparing composition |
| CN106176292A (en) * | 2016-07-16 | 2016-12-07 | 江苏华亿美素生物组织工程有限公司 | A kind of biodegradable injection molding process decorative material and preparation method thereof |
| CN107185042A (en) * | 2017-04-29 | 2017-09-22 | 杭州维多利亚医疗美容医院有限公司 | A kind of beauty injection and preparation method thereof |
| CN108324673A (en) * | 2018-02-06 | 2018-07-27 | 宁波东钱湖旅游度假区靖芮医疗美容诊所有限公司 | A kind of face mesenchyma is against age method for customizing |
| CN109528642A (en) * | 2018-12-27 | 2019-03-29 | 上海欧邦医疗管理有限公司 | A kind of autogenous repairing nutrient injection and its application method |
| CN110075366A (en) * | 2019-04-01 | 2019-08-02 | 杨青青 | A kind of anti-oxidant lifting esthetic line of biological absorbable and its preparation method and application |
| CN110368486A (en) * | 2019-08-16 | 2019-10-25 | 重庆新铜雀台整形美容医院有限公司 | A kind of injection for facial fat metabolism |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113081896A (en) * | 2021-05-10 | 2021-07-09 | 拉菲尔(深圳)投资咨询有限公司 | Regenerative medical injection for facial rejuvenation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7414021B2 (en) | Method and composition for restoration of age related tissue loss in the face or selected areas of the body | |
| US8778909B2 (en) | Method of applying an injectable filler | |
| Goldman | Hyaluronic Acid Dermal Fillers: Safety and Efficacy for the Treatment of Wrinkles, Aging Skin, Body Sculpturing and Medical Conditions. | |
| US20170106206A1 (en) | Method for non-surgical facial rejuvenation | |
| RU2383341C2 (en) | Method of skin rejuvenation | |
| CN111419780A (en) | Facial composition and application thereof | |
| CN113952277A (en) | Microcrystalline peptide anti-wrinkle face cream and preparation method thereof | |
| CN105534784A (en) | Autologous collagen firming composition | |
| US8286639B2 (en) | Method for non-surgical facial rejuvenation | |
| KR101917026B1 (en) | Cosmetic composition for skin wrinkle improvement and prevention | |
| US20210338560A1 (en) | Non-therapeutic method, uses of a substance that stimulates or generates an increase in volume | |
| RU2524610C1 (en) | Cosmetological set for lifting of soft tissues with use of meso-sutures and its application (versions) | |
| CN111991314A (en) | Freckle-removing and whitening essence | |
| Sattler et al. | Tower technique of filler injection | |
| Hau et al. | Malar reshaping technique using bidirectional barb thread suspension procedure for 3-dimensional aging in Asian faces | |
| Nelson et al. | Cosmetic Enhancement Updates and Pitfalls in Patients of Color | |
| US10272024B1 (en) | Methods for administration of cosmetic and medical agents | |
| US20140105834A1 (en) | Method for non-surgical facial rejuvenation | |
| Zhou et al. | Clinical efficacy and safety of composite non‐cross‐linked hyaluronic acid for treating tear trough‐lower eyelid bag deformity | |
| Fabi et al. | Combination Approaches: Using Fillers With Toxins and Energy-Based Devices | |
| Carruthers et al. | Botulinum toxin used in conjunction with other injectables and devices for cosmetic purposes | |
| Ibrahim et al. | Therapeutic Effect of Superficial Cryotherapy versus Intralesional Corticosteroids injection in Alopecia Areata. | |
| Tenenbaum et al. | Cosmetic Dermatology | |
| Wong | The Jawline and Neck | |
| Pratama et al. | The Current Art Combination of Platelet-Rich Plasma and Poly-D, L-Lactic Acid for Improvement of Deep Nasolabial Folds: A Case Report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200717 |
|
| RJ01 | Rejection of invention patent application after publication |